What’s Next? Five Things To Look Out For In October
Coherus To Roll Out Cimerli; Australian Price Rises Kick In
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.
You may also be interested in...
Pfizer Overcomes Attempt To Block Lexiscan ANDA
Injunctive relief has been provided against Hospira’s regadenoson ANDA product only until early October, allowing the US-based generics sponsor to close in on a potential launch.
Coherus Reveals US Launch Plans For Interchangeable Ranibizumab
Coherus has revealed further details of the firm’s plans for its Cimerli interchangeable biosimilar rival to Lucentis in the US, including a launch date and pricing information.
Coenen Named As New Medaxes Chief
Medaxes has named Jasmien Coenen as the new managing director of the Belgian off-patent industry association, following the recent passing of former leader Joris Van Assche.